Internal Medicine

A post-hoc analysis of clinical trial data found that psoriasis patients who were younger, less obese and had less severe psoriasis were more likely to achieve super-response to biologic treatment with guselkumab.

26 weeks of treatment with empagliflozin reduced the myocardial glucose metabolic rate by 45.1% in patients with type 2 diabetes.

A total of 178 patients achieved inactive disease while continuing adalimumab, and 51 patients maintained remission after discontinuing adalimumab.

Biologic agents may reduce the risk of mental health disorders among patients with moderate-to-severe psoriasis who discontinued treatment with conventional systemic agents, researchers in Canada found.

Data from this phase 2 study revealed that the efficacy and safety results support the continued investigation of mitapivat as treatment for adults with either α- or β-thalassemia who are not dependent on transfusions.

New data on the incidence of glaucoma among rural subjects ≥40 years old in China report a 0.4% annual rate.

Gary Scheiner, MS, CDE, discusses themes and topics of discussion at ADCES 22.

Called the DiaBeats algorithm, new research suggests leveraging the machine learning-based algorithm, combined with ECG recordings, could help predict increased risk of developing prediabetes and type 2 diabetes.

Both a higher self-reported water intake and a greater measured 24-h urine volume were tied to an increased DED prevalence.

New phase 3 ENHANCE-2 data support a potential submission by Verona Pharma to the FDA.

New research suggests there was a 53% greater 5-year risk of cardiovascular disease in men with type 2 diabetes who received a GnRH agonist for prostate cancer compared with their counterparts who did not receive GnRH agonists.

Data from a 14-week randomized clinical trial suggests adherence to a time-restricted diet was associated with significant differences in weight loss and improvements in blood pressure compared to a typical diet.

In October, a new ICD-10-CM diagnosis code will be activated for APDS, a rare primary immunodeficiency disease, which will enable physicians and payers to add the diagnosis to patient charts for the first time in the US.

An analysis of more than 20 years of follow-up data from more than 4000 patients in the Malmö Diet and Cancer Study shed light on associations between prostasin concentrations and risk of developing diabetes and cancer mortality.

A retrospective study provides insight into the ability of CGM technology to improve glycemic control in in-hospital settings and, potentially, reduce the risk of spreading infectious diseases.

Study data show 14% of eyes managed with intravitreal therapy in routine clinical care experienced ≥ 10 letter loss.

Investigators believe these results could help improve disease recognition and diagnosis while supporting development of personalized prevention and therapy.

Dr. David Hudesman expects drug developers to continue to target biologics for the treatment of IBD.

Repeated metabolite monitoring with subsequent dose optimization resulted in 67.2% of patients achieving therapeutic levels after 1 year and 87.8% of patients achieving steroid-free remission, while 90% had no therapy escalation or surgery.

Prior to the launch of FSR's webinar on pulmonary sarcoidosis, Mary McGowan, CEO, discusses the private listening session held with the FDA that addressed the critical needs in the field.

Dr. Gregory Weiss provides perspective on a recent study in Pediatrics describing the increased incidence of childhood obesity in the US and what it might mean for clinicians moving forward.

Patients treated with LAIAs had a lower risk of hospitalization for any cause, hospitalizations for psychiatric disorders, hospitalizations for schizophrenia, and incident suicide attempts compared to patients treated with oral antipsychotics.

An analysis of a prospective cohort study in China provides evidence suggesting poor sleep behaviors, including daytime napping and nighttime sleep disturbances, could increase risk of metabolic dysfunction-associated fatty liver disease.

The indication to Arcutis makes the once-daily topical cream the first marketed PDE4 inhibitor of its kind.

A trial assessing a 12-week fully automated, no-cost online education program suggests participation in the program was linked to a mean weight loss of 5.1% of starting body weight, with greater levels of participation linked to greater weight loss among participants.

The goal for many is to eradicate HCV by the year 2030.

The only adverse event identified was mild nausea for a duration of 10-21 days.

A randomized crossover trial assessing the effects of a 3-week time-restricted eating regimen details the impact of the approach on time in range and other glycemic measures among adults with type 2 diabetes.

The American College of Physicians (ACP) aimed to inform on the ethical decision making regarding the integration of precision medicine and genetic testing into clinical care.

Jennifer Green, MD, discusses the benefit of relatively new innovations including continuous glucose monitoring and smart insulin pens.